Sobi publishes its report for the first quarter 2016
Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) today announced its results for the first quarter 2016. Revenue for the quarter totalled SEK 1,273 M (865), an increase of 47 per cent compared to previous year. All parts of the business contributed to the result with Orfadin® and Kineret® delivering strong performance. Business Summary Q1 2016 · Initiated commercial launch of Elocta® in the first European countries; revenue in the quarter derived almost exclusively from Germany · European Commission approved transfer of marketing authorisation for Elocta to